ERBB2 and breast carcinoma: In the two decades since trastuzumab treatment was introduced, most patients with early‐stage HER2‐positive (HER2+) breast cancer have been cured, and those not cured have achieved considerable and long‐lasting improvement in quality of life and overall survival.2, 5